Cancer Communications
indexed by SCI
BMC

Review
Recent trends from the results of clinical trials on gastric cancer surgery
Takashi Kiyokawa and Takeo Fukagawa
Department of Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-Ku, Tokyo 173-8606, Japan
[Abstract] The Japan Clinical Oncology Group has recently conducted large scale clinical trials with findings that have revealed pivotal strategies for the treatment of resectable gastric cancer surgery. These findings include the fact that D3 lymphadenectomy does not improve survival rates when compared to D2 lymphadenectomy, and it is not recommended for resectable gastric cancer. Also, a transhiatal approach is recommended, instead of the left thoraco-abdominal approach, for the treatment of adenocarcinoma of the esophago-gastric junction or gastric cardia which has invaded ≤ 3 cm of the esophagus. Gastrectomy with splenectomy and bursectomy had been recommended as a part of the D2 lymphadenectomy. However, the results of the recent clinical trials revealed that splenectomy should be avoided in total gastrectomy with D2 lymphadenectomy for proximal gastric cancer and that bursectomy should be avoided in gastrectomy with D2 lymphadenectomy for resectable gastric cancer. Both splenectomy and bursectomy were found to be unable to improve survival, but instead increased operative morbidity. These trials revealed that the above-mentioned invasive and aggressive procedures did not provide sufficient survival benefits and that gastric cancer surgery may be trending from an “invasive to less invasive” and “aggressive to more conservative” approach.
Cancer Communications   Epub date: 3/27/2019   doi:10.1186/s40880-019-0360-1
[PDF Full-text]

[ Html full-text] (BioMed Central)

[ PubMed]

Cite this article

Takashi Kiyokawa and Takeo Fukagawa. Recent trends from the results of clinical trials on gastric cancer surgery. Cancer Commun (Lond). 2019, 39:11. doi:10.1186/s40880-019-0360-1


Export citations

EndNote

CJC Wechat 微信公众号


 

Editorial Manager


CC adopts Editorial Manager to manage its submissions from Dec.18, 2014

 Submission Guidelines  

 

Reference style for  

 EndNote,
 Reference Manager



Editorial Manager


 

Year:

 

Month:

Advanced search

Subscription


CC is now published by BioMed Central

© Cancer Communications

651 Dongfeng Road East, Guangzhou 510060, P. R. China